Rallybio to Present Data from the RLYB212 Phase 1b Proof-of-Concept Study at the 31st Congress of the International Society on Thrombosis and Haemostasis
2023年6月9日 - 10:15PM
ビジネスワイヤ(英語)
-- Data from the RLYB212 Phase 1b
Proof-of-Concept Study to be Featured as an Oral Presentation at
ISTH --
-- Company to Host Webcast Following ISTH
Oral Presentation of RLYB212 --
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage
biotechnology company committed to identifying and accelerating the
development of life-transforming therapies for patients with severe
and rare diseases, today announced that results from the RLYB212
Phase 1b proof-of-concept study will be presented at the 31st
Congress of the International Society on Thrombosis and Haemostasis
(ISTH), which will take place in Montreal from June 24-28. RLYB212
is an anti-HPA-1a monoclonal antibody being developed for the
prevention of fetal and neonatal alloimmune thrombocytopenia
(FNAIT).
Data from the Phase 1b RLYB212 proof-of-concept study will be
presented by Christof Geisen, M.D., as an oral presentation.
Details of the abstract presentation are as follows:
- Title: Dose-Dependent Elimination of HPA-1a Platelets by
Subcutaneous RLYB212, a Monoclonal Antibody to Prevent Fetal and
Neonatal Alloimmune Thrombocytopenia
- Presenting Author: Christof Geisen, M.D., Institute of
Transfusion Medicine and Immunohaematology, German Red Cross Blood
Transfusion Service Baden-Württemberg-Hessen gGmbH, Frankfurt am
Main, Germany.
- Abstract Presentation Number: OC 02.1
- Session Title: Bleeding and Neonatal Alloimmune
Thrombocytopenia in Pregnancy
- Session Date and Time: Saturday, June 24, 2023, from
13:00 - 14:15 (1:00 p.m. - 2:15 p.m. ET)
- Presentation Time: 13:00 - 13:15 (1:00 p.m. - 1:15 p.m.
ET), 12-minute presentation and 3-minute Q&A
The abstract can be accessed via the official ISTH 2023 Congress
website at: https://www.isth2023.org/
Investor and Analyst Meeting Webcast
Rallybio also announced today that the Company will host an
investor and analyst meeting on Saturday, June 24, 2023 from 4:00
to 6:00 p.m. ET. Institutional investors and sell-side analysts are
invited to attend in person. If you would like to attend in person,
please contact Ami Bavishi at abavishi@rallybio.com.
The meeting will include a presentation of the data from the
RLYB212 Phase 1b Proof-Of-Concept Study by Dr. Geisen, and a
corporate discussion on the RLYB212 development program. The
meeting will be webcast and can be accessed through the Events and
Presentations section of Rallybio’s website at
http://www.rallybio.com. An archived replay of the webcast will be
available following the event.
About Rallybio
Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology
company with a mission to develop and commercialize
life-transforming therapies for patients with severe and rare
diseases. Rallybio has built a broad pipeline of promising product
candidates aimed at addressing diseases with unmet medical need in
areas of maternal fetal health, complement dysregulation,
hematology, and metabolic disorders. The Company has two clinical
stage programs: RLYB212, an anti-HPA-1a antibody for the prevention
of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and
RLYB116, a C5 complement inhibitor with the potential to treat
several diseases of complement dysregulation, as well as additional
programs in preclinical development.
Rallybio is headquartered in New Haven, Connecticut with an
additional facility at the University of Connecticut’s Technology
Incubation Program in Farmington, Connecticut. For more
information, please visit www.rallybio.com and follow us on
LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements that are
based on our management’s beliefs and assumptions and on currently
available information. All statements, other than statements of
historical facts contained in this press release are
forward-looking statements. In some cases, forward-looking
statements can be identified by terms such as “may,” “will,”
“should,” “expect,” “plan,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “potential” or “continue” or the negative of these terms
or other similar expressions, although not all forward-looking
statements contain these words. Forward-looking statements in this
press release include, but are not limited to, statements
concerning results from the RLYB212 Phase 1b proof-of-concept
study, and the RLYB212 development program. The forward-looking
statements in this press release are only predictions and are based
largely on management’s current expectations and projections about
future events and financial trends that management believes may
affect Rallybio’s business, financial condition and results of
operations. These forward-looking statements speak only as of the
date of this press release and are subject to a number of known and
unknown risks, uncertainties and assumptions, including, but not
limited to, our ability to successfully initiate and conduct our
planned clinical trials, including the FNAIT natural history study,
and the Phase 1 clinical trial for RLYB212, and complete such
clinical trials and obtain results on our expected timelines, or at
all, whether our cash resources will be sufficient to fund our
operating expenses and capital expenditure requirements and whether
we will be successful raising additional capital, our ability to
enter into strategic partnerships or other arrangements,
competition from other biotechnology and pharmaceutical companies,
and those risks and uncertainties described in Rallybio’s filings
with the U.S. Securities and Exchange Commission (SEC), including
Rallybio’s Quarterly Report on Form 10-Q for the period ended March
31, 2023, and subsequent filings with the SEC. The events and
circumstances reflected in our forward-looking statements may not
be achieved or occur and actual future results, levels of activity,
performance and events and circumstances could differ materially
from those projected in the forward-looking statements. Except as
required by applicable law, we are not obligated to publicly update
or revise any forward-looking statements contained in this press
release, whether as a result of any new information, future events,
changed circumstances or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230602005343/en/
Investors Ami Bavishi Head of Investor Relations and
Corporate Communications (475) 47-RALLY (Ext. 282)
abavishi@rallybio.com Hannah Deresiewicz Stern Investor Relations,
Inc. 212-362-1200 hannah.deresiewicz@sternir.com Media Tara
DiMilia 908-369-7168 Tara.dimilia@tmstrat.com
Rallybio (NASDAQ:RLYB)
過去 株価チャート
から 4 2024 まで 5 2024
Rallybio (NASDAQ:RLYB)
過去 株価チャート
から 5 2023 まで 5 2024